GARDEN
GLOBAL HEMATOLOGICAL
RARE DISEASES ALLIANCE

Fondazione
FrancoePieraCutino
Guarire dalla
TALASSEMIA

FAD SINCRONA ECM / SYNCHRONOUS CME WEBINAR

24 | April 2026

14.00–18.30 (Italian Time)

The **Role** of **Artificial Intelligence** in the **Development** of **Data Collection** and **Prognostic factors** in **Rare Hematological Diseases**

Scientific Coordinator: Aurelio Maggio

GARDEN
WEBINARS
SERIES

a **comprensive approach**
for **breaking-up**
the **common barriers** of
**hematological
rare
diseases**

GARDEN WEBINARS SERIES

GLOBAL HEMATOLOGICAL RARE DISEASES ALLIANCE

Fondazione **Franco**e**PieraCutino**
Guarire dalla TALASSEMIA

a **comprensive approach** for **breaking-up** the **common barriers** of

hematological rare diseases

Rare hematological diseases, although individually uncommon, collectively affect millions of people worldwide. They share major challenges such as delayed diagnosis, limited access to treatments, and the need for effective patient communication.

Addressing these issues requires a multidisciplinary and international network committed to building a shared framework for action. The rapid evolution of therapies demands continuous education for healthcare professionals.

Scientific Coordinator:
Aurelio Maggio

Scientific Committee:
Aurelio Maggio

This event is part of the GARDEN Network CME Webinar Series focusing on key areas of recent progress:

Hemophilia: Updates on real-world evidence and international consensus on prophylaxis and treatment to ensure consistent standards of care;

Thalassemia and MDS: Insights into the real-life use of luspatercept and its role in improving outcomes and safety across patient populations.;

- PK Deficiency, Thalassemia, and SCD: A comparative view on mitapivat and etavopivat as targeted therapies across different rare red cell disorders;

- TTP: Challenges in real-life diagnosis and management of this hematological emergency;

- PNH: Advances in available treatments and ongoing barriers linked to cost and access;

- GENE THERAPY: Real-world evidence from European experience, marking its arrival at the patient's bedside;

- AI: Exploring new AI tools to enhance clinical data collection and support future clinical trials in rare hematological diseases.

The **Role** of **Artificial Intelligence** in the **Development** of **Data Collection** and **Prognostic factors** in **Rare** Hematological **Diseases**

Artificial Intelligence (AI) is becoming an essential tool in medical research, offering unprecedented opportunities in data management, pattern recognition, and the development of prognostic models.

In the field of rare hematological diseases - where small patient populations and fragmented data pose significant challenges - AI can support clinicians and researchers in improving diagnosis, refining prognostic factors, and enhancing patient outcomes. This educational event will bring together international experts to present the current state of AI applications in hematology, share real-world experiences, and discuss the ethical and practical aspects of integrating AI into clinical research. A specific focus will be devoted to the role of AI in advancing a new vision of thalassemia as a benign disorder of hematopoietic stem cells (HSCs). Through AI-assisted literature review and the creation of virtual patient cohorts within the GARDEN Network, it will be possible to strengthen the scientific evidence supporting this concept and to facilitate the design of more robust pharmacological trials. This methodology - already successfully applied to myelodysplastic syndromes - can be extended to other rare hematological diseases, promoting a unified data-driven research model. The ultimate goal of the webinar is to reach a consensus agreement among participants and to lay the foundation for an International GARDEN Consortium dedicated to conducting meta-analyses, building AI-supported virtual cohorts, and driving pharmacological innovation in rare hematological disorders.

Faculty

Saverio D'Amico, Milano (Italia)

Luigi De Angelis, Roma (Italia)

Mohammed Fuad Essa, Riyadh (Saudi Arabia)

Saghi Ghaffari, New York (USA)

Olivier Robert Paul Hermine, Paris (France)

Alessandro Lucchesi, Forli-Cesena (Italia)

Aurelio Maggio, Palermo (Italia)

Raffaella Origa, Cagliari (Italia)

Schott Alan Peslak, Pennsylvania (USA)

Stefano Rivella, Philadelphia (USA)

Duncan R. Smith, Bangkok (Thailand)

Alok Srivastava, Bengaluru (India)

24 | April 2026

14.00–18.30 (Italian Time)

14.00–14.10
Welcome and Introduction – A. Maggio

14.10–15.10
FIRST SESSION
Chair: A. Srivastava

Thalassemia Today from the Perspective of Conventional, Pharmacological, and Gene Therapy

14:10–14:30
The approach to the current treatment in Thalassemia
R. Origa

14.30–14.50
The pharmacological approach for curing Thalassemia
A. Maggio

14.50–15.10
Gene Addition and Gene Editing in Thalassemia: what we learnt by the real-life
M.F. Essa

The **Role** of **Artificial Intelligence** in the **Development** of **Data Collection** and **Prognostic factors** in **Rare** Hematological **Diseases**

15.10–16.10

SECOND SESSION

Chairs: L. De Angelis

Artificial Intelligence Models for Rare Diseases: The Myelodysplasia and Myeloproliferative Model

15.10–15.30
The Synthema Model: Overcoming Data Fragmentation and Scarcity in Rare Hematological Diseases
S. D'Amico

15.30–15.50
Artificial Intelligence Applications in the Diagnosis of Myeloproliferative Neoplasms
A. Lucchesi

15.50–16.10
Building Virtual Cohorts: The Role of Cohort-Based AI Approaches
S. D'Amico

24 | April 2026

14.00–18.30 (Italian Time)

16.10–17.30

THIRD SESSION

Chair: S. Rivella

The Background for a New Vision on Thalassemia

16.10–16.30
Cell Cycle Dysregulation in Thalassemia
S. Ghaffari

16.30–16.50
Mitophagy and Autophagy in Ineffective Erythropoiesis in β–Thalassemia
D.R. Smith

16.50–17.10
Molecules and Pathways Involved in Erythropoiesis: Emerging Therapeutic Targets in Thalassemia
O. Hermine

17.10–17.30
Heme–regulated inhibitors as pharmacological inducers of fetal hemoglobin
*S. Peslak*

17.30–18.30

Round Table Discussion
International Consensus
Chair: A. Maggio

13.45
Closing remarks - A. Maggio

The **Role** of **Artificial Intelligence**
in the **Development** of **Data Collection**
and **Prognostic factors** in
Rare **Hematological** **Diseases**

GARDEN
WEBINARS
SERIES

a **comprensive approach**
for **breaking-up**
the **common barriers** of
hematological
rare
diseases

ECM - EDUCAZIONE CONTINUA IN MEDICINA

Tipologia del Corso: FAD Sincrona
Durata formativa: 5 ore
Crediti ECM: n. **7,5**
ID ECM n°: **275-475509**
Professioni:
• **Medico Chirurgo** (Ematologia, Oncologia)
• **Biologo**
• **Tecnico sanitario laboratorio biomedico**
• **Infermiere**

N. partecipanti previsti: **500**
Obiettivo Formativo: 3 - Documentazione clinica.
Percorsi clinico-assistenziali diagnostici
e riabilitativi, profili di assistenza - profili di cura

Istruzioni per iscrizioni

◄ Please note that registration for the allocation of ECM credits
is valid exclusively for italian residents.

1) Inquadrare il Qr Code o collegarsi al seguente link:
https://infomed-ecm.it//event/1288/showCard

2) Cliccare su ISCRIVITI

3) Cliccare su LOGIN
(se già registrato alla piattaforma Infomed)
ed effettuare il login con le proprie credenziali.

4) Cliccare su REGISTRATI
(se non iscritto alla piattaforma Infomed)
per compilare la scheda anagrafica
e procedere all'iscrizione all'evento.

Compilazione Questionario ECM

Al termine dell'incontro, i partecipanti dovranno sostenere un
Test di Valutazione a risposta multipla e compilare il
Modulo di Qualità Percepita tramite la piattaforma:
. numero massimo di tentativi a diposizione: 1
. soglia di superamento: 75% delle risposte corrette

Test di Valutazione e Modulo di Qualità Percepita dovranno
essere compilati entro le ore **24.00 del 27/04/2026**

PROVIDER ECM N. 275 e SEGRETERIA ORGANIZZATIVA

info med
informazione&
formazione&
medicina

Via San Gregorio, 12 - 20124 MILANO (Italy)
Tel. +39 02 49453331
giovanni.bondanini@infomed-online.it
www.infomed-online.it

Partner

Con la sponsorizzazione non condizionante di:
With the unconditional sponsorship of

Fondazione
FrancoePieraCutino
Guarire dalla
TALASSEMIA

VERTEX®
THE SCIENCE *of* POSSIBILITY